Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It. With Covid deaths rising to about 1,500 per week, researchers question why Paxlovid use has remained low among high-risk patients.
The C.D.C. Director on Why You Should Get the Latest Covid Booster Here’s why the latest booster is recommended for more Americans.
How Nursing Homes Failed to Protect Residents From Covid A series of hurdles prevented the facilities from shielding older people, despite the best efforts of staff. Experts are calling for reforms before the next virus arrives.
F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment While an agency analysis did find signs of Covid “rebound,” the drug significantly reduces hospitalizations and deaths, researchers said.
Why the Odds Are Stacked Against a Promising New Covid Drug A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.